Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 21 February 2018, 08:25 HKT/SGT
Share:
    

Source: Eisai
Eisai Certified in 2018 as Outstanding Health and Productivity Management Organization (White 500)

TOKYO, Feb 21, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been certified in 2018 as an Outstanding Health and Productivity Management Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry, who organizes the Certified Health and Productivity Management Organization Recognition Program in cooperation with Nippon Kenko Kaigi which consists of leaders of medical care associations, economic associations as well as municipalities.

Under the recognition program, the Nippon Kenko Kaigi examines large enterprises, small-medium enterprises and other organizations engaging in initiatives for overcoming health-related challenges in regional communities or for promoting health-conscious activities led by the Nippon Kenko Kaigi, and recognizes outstanding enterprises engaging in efforts for health and productivity management. The five criteria for selection in the recognition program for the large enterprise category are (i) the positioning of health and productivity management in management philosophy and policies, (ii) organized frameworks established for tackling health and productivity management, (iii) specific systems established for ensuring health-conscious management as well as measures introduced for implementing them, (iv) measures established for assessing and improving health and productivity management, and (v) adherence to laws and regulations and risk management. This is the second year of the recognition program, and 541 companies were recognized as Outstanding Health and Productivity Management Organizations in the large enterprise category (White 500), along with 775 companies in the small-medium enterprise category.

Eisai's corporate philosophy is to give first thought to patients and their families and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. The maintenance and promotion of the health of employees, who are key stakeholders in the company, is an important element in actualizing this corporate philosophy, and Eisai will continue to foster initiatives for the implementation of health management in the future as well.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 31, 2025 17:27 HKT/SGT
Revenue of LEQEMBI(R) (Preliminary Basis)
July 31, 2025 08:30 HKT/SGT
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
July 31, 2025 08:20 HKT/SGT
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
July 31, 2025 08:10 HKT/SGT
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
July 29, 2025 08:01 HKT/SGT
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma
July 25, 2025 12:31 HKT/SGT
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
July 23, 2025 09:07 HKT/SGT
Launch of Beova(R) Tablets in Thailand for Overactive Bladder
July 22, 2025 10:56 HKT/SGT
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025
July 16, 2025 13:50 HKT/SGT
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
July 14, 2025 09:20 HKT/SGT
"URECE" (Dotinurad) Launched in China as a treatment for Gout
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: